Tomislav Dragovich, M.D., Ph.D., Assistant Professor of Medicine, joined University of Arizona after receiving his pharmacology training at the University of Illinois and his medical oncology training at the University of Chicago. Dr. Dragovich's research interest focuses on developing novel treatment approaches for patients with gastrointestinal malignancies (gastric, esophageal, pancreatic, hepatobiliary and colorectal cancers). Dr. Dragovich serves as a Director of the Clinical Core for the Gastrointestinal Cancer SPORE (Specialized Program of Research Excellence) that was awarded to the Arizona Cancer Center in 2002.

The ongoing clinical research protocols include: evaluation of COX-2 inhibitors (celecoxib) as anticancer therapy in patients with colorectal and pancreatic malignancies, evaluation of Thioredoxin-1 inhibitor (PX-12) in patients with advanced GI malignancies, investigations of receptor tyrosine kinase inhibitors (EGFR, PDGFR) as anticancer therapeutics, and trials of novel chemotherapeutic agents in patients with pancreatic, colorectal and hepatobiliary cancer.